Literature DB >> 17931479

Part 2: Examining pediatric vesicoureteral reflux: a real-world evaluation of treatment patterns and outcomes.

Terry W Hensle1, Grace Hyun, Amy L Grogg, Michael Eaddy.   

Abstract

OBJECTIVE: Vesicoureteral reflux (VUR) occurs in 1% of infants and children. Upon diagnosis, patients are often placed on prophylactic antibiotics to prevent urinary tract infections (UTIs) and potential renal damage. The objective of this study was to assess current diagnosis and treatment patterns for patients diagnosed with VUR, focusing on compliance with antibiotic therapy and the occurrence of UTIs.
METHODS: This is a retrospective study of children less than 11 years of age diagnosed with VUR. Data were obtained from a national managed care database with over 45 million lives. Patients were followed for up to 6 months prior to their diagnosis and 1 year after. All were required to be eligible for medical and pharmacy services for 1 year after diagnosis. Outcome measures included the use of and compliance with prophylactic antibiotics, rates of curative treatment (surgery and endoscopic injections), and diagnoses of UTIs.
RESULTS: There were 35 450 patients meeting inclusion criteria. After being diagnosed with VUR, 76.5% of patients were placed on prophylactic antibiotics, 1.5% had open surgery, and 0.38% had an endoscopic injection with dextranomer/hyaluronic acid copolymer (Dx/HA). Only 17% of patients on prophylactic antibiotics were adherent to therapy, with mean patient compliance equaling 41.4%. Of patients on prophylactic antibiotic therapy, 58% still had a diagnosis for a UTI within 12 months of VUR diagnosis. LIMITATIONS: Adherence to VUR-related antibiotic therapy may be overestimated as the data used in the analysis represents prescriptions acquired but not necessarily consumed. This study lacked detailed clinical information, such as VUR-resolution rates and VUR grade.
CONCLUSIONS: Only 17% of pediatric VUR patients on prophylactic antibiotics were compliant with therapy. Of patients on prophylactic therapy, 58% had a diagnosis of a UTI within 1 year of treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931479     DOI: 10.1185/030079907X226221

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  16 in total

1.  Medical versus surgical management for vesicoureteric reflux: the case for medical management.

Authors:  Armando J Lorenzo
Journal:  Can Urol Assoc J       Date:  2010-08       Impact factor: 1.862

2.  Uropathogen Resistance and Antibiotic Prophylaxis: A Meta-analysis.

Authors:  Rachel E Selekman; Daniel J Shapiro; John Boscardin; Gabrielle Williams; Jonathan C Craig; Per Brandström; Marco Pennesi; Gwenalle Roussey-Kesler; Pankaj Hari; Hillary L Copp
Journal:  Pediatrics       Date:  2018-07       Impact factor: 7.124

3.  Altered expression of c-kit-positive cells in the ureterovesical junction after surgically created vesicoureteral reflux.

Authors:  Zsolt Oberritter; Udo Rolle; Zsolt Juhasz; Tamas Cserni; Prem Puri
Journal:  Pediatr Surg Int       Date:  2009-10-24       Impact factor: 1.827

Review 4.  Relevance of current guidelines in the management of VUR.

Authors:  Alexander Springer; Ramnath Subramaniam
Journal:  Eur J Pediatr       Date:  2014-01-03       Impact factor: 3.183

Review 5.  Long-term, low-dose prophylaxis against urinary tract infections in young children.

Authors:  Per Brandström; Sverker Hansson
Journal:  Pediatr Nephrol       Date:  2014-06-07       Impact factor: 3.714

6.  Compliance with antibiotic prophylaxis in children with vesicoureteral reflux: results from a national pharmacy claims database.

Authors:  Hillary L Copp; Caleb P Nelson; Linda D Shortliffe; Julie Lai; Christopher S Saigal; William A Kennedy
Journal:  J Urol       Date:  2010-03-19       Impact factor: 7.450

7.  Acute left flank pain.

Authors:  Beatrice Hoffmann
Journal:  Int J Emerg Med       Date:  2009-05-29

Review 8.  Therapy for vesicoureteral reflux: antibiotic prophylaxis, urotherapy, open surgery, endoscopic injection, or observation?

Authors:  Jack S Elder
Journal:  Curr Urol Rep       Date:  2008-03       Impact factor: 3.092

9.  [Long-term results after endoscopic subureteral injection for VUR using dextranomer/hyaluronic acid copolymer : a five years experience].

Authors:  J Seibold; M Werther; K-D Sievert; A Stenzl
Journal:  Urologe A       Date:  2010-04       Impact factor: 0.639

Review 10.  Antibiotic prophylaxis in antenatal nonrefluxing hydronephrosis, megaureter and ureterocele.

Authors:  Marco Castagnetti; Marcello Cimador; Ciro Esposito; Waifro Rigamonti
Journal:  Nat Rev Urol       Date:  2012-05-08       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.